I型干扰素通路激活与风湿及肌肉骨骼疾病临床结局的关联:为EULAR考虑要点提供信息的系统文献综述
该系统文献综述检索三个数据库,评估I型干扰素通路激活检测在风湿及肌肉骨骼疾病诊断、疾病活动度、预后、治疗反应及检测反应性中的应用。共筛选366篇文献,纳入276项研究,发现检测方法、分析条件、偏倚风险及疾病应用存在显著异质性,I型干扰素通路激活与SLE疾病活动度和 flare 发生相关,但增量价值不确定,可能预测对I型干扰素靶向治疗及其他治疗的反应,结论认为检测具有潜在临床价值但亟需检测标准化和临床验证。
要点
- I型干扰素通路激活检测在风湿及肌肉骨骼疾病中具有潜在临床价值。
- I型干扰素通路激活与SLE疾病活动度和 flare 发生相关,但增量价值不确定。
- I型干扰素通路激活可能预测对I型干扰素靶向治疗及其他治疗的反应。
核心结论
- 证据表明测量I型干扰素通路激活的检测在多种风湿及肌肉骨骼疾病中具有潜在临床价值,但亟需检测标准化和临床验证。
- 本综述为EULAR关于I型干扰素通路检测测量和报告的考虑要点提供信息。
研究设计与样本
- 系统文献综述,检索三个数据库,评估I型干扰素检测在多种风湿及肌肉骨骼疾病诊断、疾病活动度监测、预后、治疗反应及检测反应性中的应用。
- 筛选366篇文献,纳入276项研究,其中报告用于疾病诊断n=188、疾病活动度评估n=122、预后n=20、治疗反应n=23、检测反应性n=59。
主要发现
- 免疫检测、定量PCR(qPCR)和微阵列报告最多,系统性红斑狼疮(SLE)、类风湿关节炎、肌炎、系统性硬化症和原发性干燥综合征是研究最多的风湿及肌肉骨骼疾病。
- 文献显示技术在方法、分析条件、偏倚风险及疾病应用方面存在显著异质性。
- I型干扰素通路激活与SLE疾病活动度和 flare 发生相关,但其增量价值不确定。
- I型干扰素通路激活可能预测对I型干扰素靶向治疗的反应,并可能预测对不同治疗的反应。
局限性
- 研究设计不充分和技术异质性是主要局限性。
- 文献显示技术在方法、分析条件、偏倚风险及疾病应用方面存在显著异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Type I interferons (IFN-I) contribute to a broad range of rheumatic and musculoskeletal diseases (RMDs). Compelling evidence suggests that the measurement of IFN-I pathway activation may have clinical value. Although several IFN-I pathway assays have been proposed, the exact clinical applications are unclear. We summarise the evidence on the potential clinical utility of assays measuring IFN-I pathway activation. METHODS: A systematic literature review was conducted across three databases to evaluate the use of IFN-I assays in diagnosis and monitor disease activity, prognosis, response to treatment and responsiveness to change in several RMDs. RESULTS: Of 366 screened, 276 studies were selected that reported the use of assays reflecting IFN-I pathway activation for disease diagnosis (n=188), assessment of disease activity (n=122), prognosis (n=20), response to treatment (n=23) and assay responsiveness (n=59). Immunoassays, quantitative PCR (qPCR) and microarrays were reported most frequently, while systemic lupus erythematosus (SLE), rheumatoid arthritis, myositis, systemic sclerosis and primary Sjögren's syndrome were the most studied RMDs. The literature demonstrated significant heterogeneity in techniques, analytical conditions, risk of bias and application in diseases. Inadequate study designs and technical heterogeneity were the main limitations. IFN-I pathway activation was associated with disease activity and flare occurrence in SLE, but their incremental value was uncertain. IFN-I pathway activation may predict response to IFN-I targeting therapies and may predict response to different treatments. CONCLUSIONS: Evidence indicates potential clinical value of assays measuring IFN-I pathway activation in several RMDs, but assay harmonisation and clinical validation are urged. This review informs the EULAR points to consider for the measurement and reporting of IFN-I pathway assays.
引用
- Rodríguez-Carrio J, Burska A, Conaghan PG, et al. Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. RMD Open. 2023. PMID: 36882218. doi:10.1136/rmdopen-2022-002864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。